Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...
Rolling Out4h
Kidney disease speeds up heart risks, study finds
Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.
Do You Have Puffy Eyes Or Swollen Ankles? It Could Be Chronic Glomerulonephritis
The treatment procedures are required in the case of the severity of the condition. The patient then needs to go for a kidney ...
Medscape3d
‘Yo-Yo Dieting’ Raises Kidney Disease Risk in T1D
Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...
Daily4h
Kidney parenchyma fat content similar between healthy controls and diabetes patients regardless of CKD status: Study
Denmark: A recent study published in the Journal of Diabetes and its Complications has explored the role of kidney fat ...
The Daily Mirror1h
This year the day falls on March 13 Series of events planned to mark World Kidney Day
The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...
infectiousdiseaseadvisor.com4d
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Business Insider2d
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
1 uACR is a sensitive measure of proteinuria across stages of glomerular kidney disease, particularly in hypertension and diabetes, and has been used to assess risk of cardiovascular disease.